CANCER DRUG DEVELOPMENT PIPELINE
Oncology Drug Pipeline & Cancer Clinical Trials
Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
Oncology Pipeline & Trials
Oncology Pipeline as of July 28, 2021
- Discovery Projects
- 16Phase 1
- 7Phase 2
- 8Phase 3
- 1Registration
- Total32
| Compound Name | Indication | Phase | Submission Type | Compound Type |
|---|---|---|---|---|
Lorbrena (lorlatinib) Therapeutic Area: Oncology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: ALK inhibitor | 1st Line ALK Non-Small Cell Lung Cancer (E.U.) | Registration | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | 1st Line Non-Small Cell Lung Cancer (Biologic) | Phase 3 | Product Enhancement | Biologic |
Ibrance (palbociclib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: CDK 4,6 kinase inhibitor | ER+/HER2+ Metastatic Breast Cancer(PATINA) | Phase 3 | Product Enhancement | Small Molecule |
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti-PD-1 | Non-Muscle-Invasive Bladder Cancer (Biologic) | Phase 3 | New Molecular Entity | Biologic |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | Combo w/ Xtandi (enzalutamide) for DDR-deficient Metastatic Castration Sensitive Prostate Cancer
Project advanced | Phase 3 | Product Enhancement | Small Molecule |
Xtandi (enzalutamide) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: Androgen receptor inhibitor | Non-metastatic High-Risk Castration Sensitive Prostate Cancer | Phase 3 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor and anti PD-1 | BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma | Phase 3 | Product Enhancement | Small Molecule |
Braftovi (encorafinib) + Erbitux® (cetuximab) Therapeutic Area: Oncology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor and anti EGFR | 1st line BRAF-mutant Metastatic Colorectal Cancer | Phase 3 | Product Enhancement | Small Molecule |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/CMP-001 for Head and Neck Cancer (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) | Phase 2 | Product Enhancement | Biologic |
Bavencio (avelumab) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: Anti PD-L1 | Combo w/Talzenna (talazoparib) for Solid Tumors with a BRCA or ATM defect (Biologic) | Phase 2 | Product Enhancement | Biologic |
Braftovi (encorafinib) + Mektovi (binimetinib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: BRAF kinase inhibitor andMEK inhibitor | 1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer | Phase 2 | Product Enhancement | Small Molecule |
Talzenna (talazoparib) Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PARP inhibitor | 2nd Line Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Product Enhancement | Small Molecule |
Elranatamab Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Biologic Business Segment: Biopharma Mechanism of Action: BCMA-CD3 Bispecific Antibody | Multiple Myeloma Triple-Class Refractory (Biologic) | Phase 2 | New Molecular Entity | Biologic |
ARV-471 Therapeutic Area: Oncology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: ER-targeting PROTAC® protein degrader | ER+/HER2- Metastatic Breast Cancer
Project advanced | Phase 2 | New Molecular Entity | Small Molecule |
PF-06647020 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity | Cancer (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06821497 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: EZH2 Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-06873600 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 2,4,6 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-06939999 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: protein arginine methyltransferase 5 (PRMT5) Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
PF-06940434 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: Integrin alpha-V/beta-8 Antagonist | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-06952229 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: transforming growth factor, beta receptor 1 (TGFBR1) Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
PF-07062119 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: GUCY2c CD3 Bispecific Antibody | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07104091 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK2 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-07209960 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: interleukin 15 (IL15) Activator | Solid Tumors (Biologic) | Phase 1 | New Molecular Entity | Biologic |
PF-07220060 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK4 Inhibitor | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-07265807 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: AXL/MERTK Inhibitor | Solid Tumors | Phase 1 | New Molecular Entity | Small Molecule |
PF-07248144 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: KAT6A Epigenetic modifier | Breast Cancer Metastatic | Phase 1 | New Molecular Entity | Small Molecule |
PF-07284890 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: BRAF kinase Inhibitor | Melanoma | Phase 1 | New Molecular Entity | Small Molecule |
PF-07284892 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: SHP2 tyrosine phosphatase Inhibitor | Cancer | Phase 1 | New Molecular Entity | Small Molecule |
ARV-471 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: ER-targeting PROTAC® protein degrader | ER+/HER2- Metastatic Breast Cancer
Project advanced | Phase 1 | Product Enhancement | Small Molecule |
Ibrance + ARV-471 Therapeutic Area: Oncology Phase:Phase 1 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: CDK 4,6 kinase inhibitor + ER-targeting PROTAC® protein degrader | ER+/HER2- Metastatic Breast Cancer
Project advanced | Phase 1 | Product Enhancement | Small Molecule |
![iStock-1199449498_380x300[1].jpg](https://cdn.pfizer.com/pfizercom/styles/style_300_170/s3/2021-09/iStock-1199449498_380x300%5B1%5D.jpg?pYyJpQdhyvaU22v13JPyau8ro2rGk0CR&itok=pJGCW7Vt)
